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Abstract
Chronic kidney disease (CKD) is a globally recognized public health concern. Multiple 
studies have shown the association of CKD with cardiovascular mortality that persists 
after adjustment for traditional cardiovascular disease (CVD) risk factors. CKD causes 
accelerated coronary artery disease (CAD). In this chapter, we discuss the pathophysi‐
ological mechanisms that play a role in increasing CVD risk in patients with CKD. 
Further we delve into some commonly encountered challenges related to CVD in 
patients with CKD. These include revascularization challenges, contrasted induced 
nephropathy and alterations in traditional risk factors for CVD in renal transplant 
patients.
Keywords: coronary artery disease, chronic kidney disease, mortality, morbidity, public 
health
1. Introduction
Chronic kidney disease (CKD) is recognized as a major global public health problem [1]. 
It is estimated that 10–25% of population from Asia, Australia, Europe and United States of 
America (USA) is affected by CKD [2–6].
Multiple studies have shown the association of CKD with cardiovascular mortality that 
 persists after adjustment for traditional cardiovascular disease (CVD) risk factors. These 
include the Atherosclerosis Risk in Communities study (ARIC) and the Cardiovascular 
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Health Study [7–9]. The risk of developing congestive heart failure, atrial fibrillation, stroke, 
coronary artery disease (CAD) and peripheral artery disease (PAD) is increased twofold in 
patients with glomerular filtration rate (eGFR) < 70ml/min/1.73m2 [8, 10]. Furthermore, in two 
separate meta‐analyses of twenty‐one studies from fourteen different countries eGFR and 
albuminuria were found to be independently associated with increased risk of all‐cause and 
cardiovascular mortality [11, 12].
In this chapter we discuss the acute and chronic cardiovascular impact of patients with 
reduced kidney function. We further delve in evaluation of coronary artery disease in patients 
with CKD. We also address the cardiovascular aspects of patient care in renal transplant 
patients including modification of traditional CVD risk factors in patients taking immuno‐
suppressive therapy.
2. Epidemiology
CKD is a globally recognized public health burden [13]. USA alone deals with a population 
of more than 20 million people with CKD [14]. Data from other developed and developing 
nations confirms the rising trend of the disease. Data from China estimates this number to be 
close to 100 million Chinese being affected with CKD [15].
CKD has long shared its associations with CVD. The prevalence of CVD among patients 
with CKD has been known across trials in USA, Japan, Spain, United Kingdom and, recently, 
across China. Highest prevalence was found in U.K., 47.2% followed by Spain, 39.1%, U.S., 
33.4%, Japan, 26.8% and China 9.8% [16–19].
United States Renal Data System (USRDS) reports from 2016 revealed the prevalence of any 
cardiovascular event to be twice among those with CKD compared to those without it, 68.8% 
vs. 34.1% respectively.
2.1. Linear relationship of cardiovascular mortality with EGFR
CKD is an independent risk factor for progression to cardiovascular disease, known to con‐
tribute to cardiovascular morbidity and mortality [20]. Go et al., using longitudinal measure‐
ment of estimated eGFR, demonstrated the inverse relationship between eGFR and mortality 
rate secondary to cardiovascular events, below an eGFR of 60 ml/min per 1.73 m2 [21]. A meta‐
analysis from 2011, comprising a grand total of 266,975 patients reported an exponential rise 
in mortality with eGFR below 60 ml/min per 1.73 m2 [22]. (21,307,840) For cardiovascular mor‐
tality, adjusted hazard ratios at eGFR 60, 45, and 15 ml/min per 1.73 m2 were 1.11 (0.93–1.32), 
1.73 (1.49–2.00), and 3.08 (1.89–5.01), respectively [22].
Manjunath et al., also demonstrated eGFR as an independent risk factor for progression to 
CVD [23]. In a sample population of 4893, subjects with GFR 90 mL/min/1.73 m2 had a 15% risk 
of CVD over 3 years while subjects with GFR 30 mL/min/1.73 m2 had a 40% risk of CVD [23]. 
These findings were independent from traditional risk factors of cardiovascular diseases.
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2.2. Albuminuria a marker of worse cardiovascular outcomes in CKD patients
Abuminuria has been proven to be a significant risk factor for all cause and CVD related mor‐
tality in patients with CKD. Pooled data from Van der Welde et al., demonstrated a significant 
increase in cardiovascular mortality in patients with Albumin‐to‐creatinine ratio of 10 mg/dl 
compared to 5 mg/dl [22]. Similar results demonstrating an association of CVD mortality with 
albuminuria have been reported in other large scale studies [11, 12].
3. Ischemic heart disease in chronic kidney disease
3.1. Background
Cardiovascular (CV) mortality is the leading cause of death in CKD patients and the risk of 
CV mortality increases with decrease in eGFR. Most of the burden of CV mortality in CKD 
patients is secondary to ischemic heart disease or complications associated with it including 
congestive heart failure. The severity and incidence of CAD increases as the kidney function 
declines with the prevalence of multi‐vessel CAD and left main disease being significantly 
higher in the CKD population [24].
Coronary arteries in CKD patients have shown to exhibit more extensive atherosclerosis [25]. 
Multiple studies have shown the association of CKD with cardiovascular mortality that 
persists after adjustment for traditional cardiovascular disease (CVD) risk factors [26, 27]. 
Mineralocorticoid excess, oxidative stress and cellular inflammation are linked to plaque for‐
mation and rupture in CKD patients. Vitamin D deficiency a common sequela of CKD could 
explain the propensity of CKD patients to develop CAD. It has been shown that patients 
with Vitamin D deficiency have higher risk of myocardial infarction (MI). Similarly fibroblast 
growth factor 23 (FGF 23) a hormone usually elevated in CKD patients, to mitigate hyper‐
phosphatemia was associated with increased CVD mortality in patients with CKD [28, 29].
In summation, the pathophysiological basis of increased CVD risk and severity in patients 
with CKD is due to a complex interplay of factors involving hormonal and immune mediated 
responses. However the risk of CAD in CKD has been well established. Hence in 2013 the 
American Heart Association (AHA) issued a statement to classify CKD as an independent risk 
factor for developing CVD [30].
3.2. Revascularization in CKD patients with stable CAD
Management of patients with established CAD and CKD is challenging. Medical manage‐
ment in patients with renal dysfunction has been based on therapy shown to be beneficial in 
patient population without CKD. These medications include aspirin, beta‐blockers, nitrates, 
hydroxymethylglutaryl co‐enzyme A reductase inhibitors (statins) and angiotensin convert‐
ing enzyme inhibitors. However because of routine exclusion of CKD patients from clinical 
trials, the efficacy of these agents in patients with CKD is still unclear.
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No robust evidence is yet available to ascertain whether CKD patients with chronic stable 
angina who undergo revascularization have a definite survival advantage compared to CKD 
patients on medical therapy alone. In the only randomized study of dialysis patients compar‐
ing invasive approach (PCI and coronary artery bypass graft surgery (CABG)) with  medical 
therapy alone, the invasive approach had a clear survival benefit [31]. However medical 
therapy at that time only consisted of calcium channel blockers, and use of other agents 
proven to have survival advantage in patients with cardiovascular disease was not the norm. 
Furthermore, this study only included patients with diabetes mellitus. In another study done 
in 2002, PCI did not significantly improve survival [32].
Multiple studies have found that patients with CKD who undergo revascularization for CAD 
have worst outcomes compared to patients with normal kidney function [32, 33]. Patients 
with CKD have more cardiovascular risk factors at baseline [32]. Furthermore, CKD itself was 
independently associated with worst outcomes including increased all‐cause mortality and 
subsequent cardiac events [32].
In CKD revascularization procedures including percutanous coronary intervention (PCI) and 
coronary artery bypass graft surgery (CABG) are complicated by risk of contrast induced 
nephropathy (CIN) and increased risk of bleeding due to dual antiplatelet therapy. CIN is 
discussed in detail in separate section.
CKD results in complex hemostatic disorder manifested by increased bleeding and thrombo‐
sis. Hence the use of antiplatelet therapy has the potential for both benefit and harm. Reduced 
platelet aggregation, intrinsic platelet dysfunction and abnormalities in platelet‐endothelial 
interactions are found in CKD and may in part account for increased bleeding risk with PCI 
in these patients [34–36].
On the contrary, some studies have suggested the presence of pro‐thrombotic state in CKD 
patients that manifest by an increase in serum fibrinogen, von Willibrand factor and reduc‐
tion in antithrombin 3 [34, 37–39]. Therefore, it is unclear whether dual antiplatelet therapy 
after PCI is beneficial and safe in CKD patients. Furthermore, few studies have evaluated the 
appropriate dosing of antithrombotic agents or anticoagulants in patients with CKD [40].
Although clinical restenosis rates are not higher compared to patients with normal renal func‐
tion, on repeated angiography restenosis rates were found to be as high as 60–81% [41, 42]. 
Thus, absence of symptoms of restenosis in patients with chronic renal insufficiency may lead 
to silent ischemia and contribute to high risk of subsequent cardiac events.
CKD patients have worse outcomes after CABG. One study found in‐hospital mortality rate 
to be 14.6% [43]. Another study that was done on end‐stage renal disease (ESRD) patients 
over course of 10 years found peri‐operative mortality to be about 14% in cardiac surgery 
patients [44]. Even mild renal insufficiency is associated with double in‐hospitality rates in 
one analysis [45]. CAD is more diffuse in patients with renal dysfunction which likely contrib‐
utes higher complication rates and worst outcomes.
Szczech et al. published a study in 2001 that showed survival benefit among patients with ESRD 
undergoing CABG as compared to PCI, while controlling for severity of CAD, LV dysfunction 
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and other comorbid conditions [46]. However in analysis of CREDO‐Hyoto PCI/CABG reg‐
istry Marui A et al. found CABG relative to PCI reduced risk of cardiac death, sudden death, 
myocardial infarction and need for revascularization in patients with left main disease or 
multi‐vessel CAD only [47]. In a study by Banglore et al., revascularization with Everolimus 
eluting stensts was compared to CABG in patients with CKD. The authors concluded that 
CABG was associated with higher short term risk of death, stroke and repeat revasculariza‐
tion, whereas PCI with everolimus‐eluting stent was associated with higher long‐term risk of 
revascularization and perhaps MI [48]. Current American College of Cardiology (ACC) and 
American Heart Association (AHA) guidelines recommend CABG for patients with left main 
or multi‐vessel disease irrespective of renal function.
3.3. Non‐invasive cardiac imaging in patients with CKD
As already mentioned CKD patients are at a higher risk of CVD. Imaging plays a central role 
in risk stratification and assessment of severity of CAD. A range of imaging modalities have 
been developed to assist with diagnosis and risk stratification of CVD in patients with CKD.
Myocardial perfusion imaging (MPI) is widely used for non‐invasive assessment of myocar‐
dial ischemia due to CAD [49]. MPI can be performed using single photon emission computed 
tomography (SPECT) as well as positron emission tomography (PET). SPECT MPI is more 
widely available. It can be performed with a variety of stressors such as exercise or administra‐
tion of vasodilatory agents (adenosine or regadenoson) or dobutamine. SPECT detects areas of 
reduced perfusion by measuring and comparing the distribution of injected radioactive trac‐
ers such as 99 technetium or 201 thallium, when at rest and after stressor/vasodilator agents.
For PET MPI stress perfusion is measured in the same way as SPECT. Various agents can be 
used as radiotracer including H2 15 O, ammonia or rubidium. With PET absolute quantifica‐
tion of myocardial blood flow is possible. Although both SPECT and PET MPI have widely 
been studied for detection of CAD in general population, data regarding their use in CKD 
population in limited.
Echocardiography plays a pivotal role in assessment of cardiac dysfunction in patients with 
or without renal insufficiency. Various cardiac abnormalities including left ventricular hyper‐
trophy (LVH), diastolic or systolic dysfunction are predictive of poor prognosis in CKD 
patients and can be rapidly diagnosed using 2 D trans‐thoracic echocardiogram (TTE). Stress 
echocardiography is an established technique used to investigate myocardial viability and 
ischemia. Patients can be stressed either pharmacologically with dobutamine or with exer‐
cise [50]. However, the sensitivity and specificity of stress echocardiography is modest in 
patients with CKD. In a systemic review by Sharma et al. sensitivity of stress echocardiogra‐
phy was 80% in patients with ESRD [51]. Factors limiting the role of stress echocardiography 
for detecting CAD in patients with CKD include LVH and blunted chronotropic response in 
patients with CKD [52, 53].
CT coronary angiography (CTA) has good sensitivity and specificity for detection of CAD in non‐
CKD population [54]. However, data is limited in patients with CKD. Iodinated contrast agent is 
required that increases the risk of contrast induced nephropathy. (contrast induced nephropathy 
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is discussed in separate section) Furthermore concerns exist that diffuse calcifications in CKD 
patients might render interpretation of CTA findings difficult. In patients on hemodialysis (HD) 
calcifications can occur in intima, where it contributes to luminal stenosis or medial where it is 
related to vascular stiffness. CTA might not be able to discern the difference. Despite these limi‐
tations some small studies have reported > 90% sensitivity of CTA to detect CAD in patients on 
HD [55]. However, coronary angiography was not used as gold standard in these studies.
Leading authors have advocated for combining functional imaging technique with anatomi‐
cal imaging technique for CAD screening in clinical practice. Although these hybrid tech‐
niques are potentially useful in general population, none have been validated in patients with 
CKD [56, 82]. Role of non‐invasive imaging for pre‐transplant evaluation of CAD is addressed 
in a separate section.
3.4. Contrast Induced Nephropathy
PCI in patients with CKD is challenging due to presence of complex calcified lesions and the 
very high risk of CIN. PCI in patients with advanced CKD is associated with increased risk of 
CIN which is independently associated with major adverse clinical events [57]. Outcomes are 
even worse if renal replacement therapy is required [57].
Pathophysiologically several mechanisms are involved in acute kidney injury caused by 
CIN. Studies have shown evidence of acute tubular necrosis (ATN). Two mechanism of ATN 
have been postulated. Direct nephrotoxicity of contrast agents has been documented [58, 59]. 
Furthermore, it has also been hypothesized that renal vasoconstriction, mediated by endothelin 
and prostaglandins resulting in medullary hypoxia causes ATN [60–62].
Studies have demonstrated a dose‐dependent relationship of acute kidney injury (AKI) caused 
by CIN [63]. The type of contrast alters the risk of CIN. The use of first generation hyperosmo‐
lar ionic agents is associated with a greater risk of CIN [64]. Prevention strategies for CIN that 
have been well established also apply to patients undergoing PCI. These include using minimal 
amount of contrast, avoiding ionic contrast and non‐steroidal anti‐inflammatory drugs (NSAIDs).
Most recently Galougahi et al. have described a case series of a unique approach toward 
revascularization in patients with CKD by sequential diagnostic angiography using ultra‐
low volumes of contrast followed by staged physiology and intravascular ultrasound (IVUS)‐
guided zero contrast PCI in three patients with severely calcified coronary lesions [65]. While 
such strategies have potential for more wider acceptance, at this time they are not practiced 
widely due to technical and procedural limitations.
4. Use of troponin concentration level in patients with chronic kidney 
disease
Troponin proteins are present in both cardiac and skeletal muscle [66]. Cardiac troponin C 
is identicial to troponin C expressed in skeletal muscle. However cardiac troponin TnT and 
TnI are each derived from genes that are specific to the heart [66]. Hence troponin T (cTnT) 
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and Troponin I (cTnI) are considered the preferred biochemical markers to detect myocar‐
dial injury and to diagnose acute myocardial infarction (AMI). Since the introduction of high 
 sensitivity cardiac troponin (hs‐cTn) assays, more accurate detection of low levels of circulat‐
ing cardiac troponins became feasible [67].
However the increase in sensitivity of hs‐cTn for AMI is accompanied by decrease in specific‐
ity [68, 69]. In patients with chronic kidney disease elevated hs‐cTn concentrations are associ‐
ated with reduced renal function.
The interpretation of serum markers for myocardial injury in patients with renal insufficiency 
remains controversial. Large scale trials of patients with acute coronary syndrome (ACS) have 
documented the importance of troponin elevations in risk stratification, prognosis and thera‐
peutic utilization. However most of these studies excluded patients with renal insufficiency.
Cardinaels et al. recently showed that in patients with acute chest discomfort hs‐cTnT and hs‐
cTnI were strongly correlated with eGFR [70]. Although differences were small, the authors 
reported a greater correlation of hs‐cTnT with eGFR compared to hs‐cTnI. Furthermore, the 
association of hs‐cTnT is greater with eGFR as compared to any other cardiac parameters 
including coronary plaque severity, coronary calcium score and left ventricular structure [70]. 
In contrast to hs‐TnT, hs‐TnI has a greater association with LV mass compared to eGFR. Hence 
it is possible that hs‐TnT is more susceptible to renal clearance then hs‐cTnI. However, these 
differences are yet to be completely established.
Furthermore, many investigators have hypothesized uremic‐induced skeletal myopathy 
may be responsible for increased troponins in patients with renal failure [66]. This conclu‐
sion is centered on the notion that uremia may promote re‐expression of cardiac TnT from 
injured or regenerating cardiac muscle fibers. Some anecdotal reports show elevated serum 
TnT levels in patients with skeletal muscle injury or inflammatory myopathies in the absence 
of any obvious myocardial ischemia [71, 72]. In marathon runners without any history of cor‐
onary artery disease cardiac TnT levels were elevated after running a marathon [73]. Hence 
cardiac troponin levels may be elevated in patients with renal insufficiency in the absence 
of AMI due to increased production from skeletal muscles and possible due to decreased 
renal clearance. It is imperative to evaluate troponin concentrations in patients with CKD in 
proper clinical context and utilization of other resources such as Electrocardiogram (EKG) 
to rule out AMI.
5. Cardio‐renal Syndromes
The heart and kidneys work together to manage blood pressure, electrolyte and fluid excre‐
tion, but most importantly extracellular fluid balance [74]. Cardio‐renal syndrome (CRS) is 
defined as a broad spectrum of diseases where both the heart and kidneys are involved in an 
acute or chronic setting [75]
There are five types of CRSs. Type I, or acute CRS, is acute heart failure leading to acute 
 kidney injury [74] Type II, or chronic CRS, occurs in the setting of chronic heart failure which 
leads to kidney injury [75]. Type III or acute nephrocardiac is caused by acute kidney injury 
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leading to acute heart failure, example Uremic cardiomyopathy [75]. Type IV, or chronic 
nephrocardiac, occurs with chronic kidney disease which causes heart failure for example 
diastolic heart failure and kidney failure [75]. Lastly, is type V which is secondary to systemic 
disease leading to heart and kidney failure [75]. Table 1 summarizes the five types of CRSs.
Management of patients with acute decompensated heart failure and worsening renal func‐
tion can be challenging. A randomized control trial compared the effect of venovenous ultra‐
filtration with intravenous diuretics on renal function with acute decompensated heart failure 
and worsening renal function [76]. This study found that there was no significant difference 
between diuretics and ultrafiltration in weight loss, mortality or the rate of re‐hospitalization 
for acute decompensated heart failure during a 60 day follow‐up.
6. CAD evaluation before kidney transplant
Cardiovascular disease is the leading cause of morbidity and mortality in patients with 
end‐stage renal disease (ESRD) and in those after kidney transplant [77, 78]. Based on 
Medicare billing claims incidence of myocardial infarction have ranged from 8.7 to 16.7% 
by 3 years after kidney transplant listing and from 4.7 to 11.1% after kidney transplanta‐
tion [79]. Cardiovascular disease accounts for 30% of the overall mortality especially in 
the peri‐transplantation period [80]. So, the preoperative cardiovascular risk assessment 
is of high importance before the kidney transplant surgery as these patients are closely 
followed up for over the 3 years and events are reported to the United Network for Organ 
Sharing (UNOS).
Figure 1 summarizes a clinical approach to preoperative cardiovascular risk assessment 
before kidney transplantation.
Cardiorenal type Inciting event Secondary event Example
Type I Acute heart failure Acute kidney injury Acute coronary syndrome 
leading to decreased cardiac 
output and acute kidney injury
Type II Chronic heart failure Progressive kidney disease Chronic heart failure leading to 
decreased cardiac output
Type III Acute kidney injury Acute cardiac disease (heart 
failure, arrhythmia, pulmonary 
edema)
Acute kidney failure (drug 
induced, glomerulonephritis)
Type IV Chronic kidney disease Decreased cardiac output, 
Increased blood pressure leading 
to cardiac hypertrophy
Chronic kidney disease due 
to chronic hypertension or 
diabetic nephropathy
Type V Systemic disease Both kidney and heart 
dysfunction and disease
diabetes mellitus, sepsis, lupus
Table 1. Classification of cardio‐renal syndromes.
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Figure 1. Pre‐operative cardiovascular risk assessment before kidney transplant.
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Step 1: Assess for presence of active cardiac condition:
Patients with active cardiac condition should be ruled out by detailed history and physical 
examination. Active cardiac conditions include‐ unstable coronary syndromes (e.g., unstable 
angina, severe angina, or recent MI), decompensated heart failure, significant arrhythmias, 
and severe valvular disease. The presence of one or more of these conditions is associated 
with high rates of perioperative cardiovascular morbidity and mortality and may require 
delay or cancellation of surgery.
Step 2: Assess for presence of risk factors
After excluding active cardiac condition, presence of risk factors for CAD should be assessed. 
Traditional Framingham risk score has modest to moderate ability to predict long‐term 
coronary events among kidney transplantation patients. Risk stratification based on 2007 
Lisbon conference [81] strategy improved the sensitivity and specificity for the identifica‐
tion of CAD (sensitivity, 94% vs. 77%; specificity, 33% vs. 24%) when compared to ACC/
AHA recommended CAD risk stratification strategy The risk factors for CAD Aeemed rel‐
evant to transplantation candidates in the Lisbon Conference report include diabetes mellitus, 
prior cardiovascular disease, >1 year on dialysis, left ventricular hypertrophy, age > 60 years, 
 smoking, hypertension, and dyslipidemia.
Currently, the preoperative assessment is done based on the ACC/AHA scientific statement 
[78]. As per this “Noninvasive stress testing may be considered in kidney transplantation 
candidates with no active cardiac conditions based on the presence of multiple coronary 
artery disease (CAD) risk factors regardless of functional status. Relevant risk factors among 
transplantation candidates include diabetes mellitus, prior cardiovascular disease, more than 
1 year on dialysis, left ventricular hypertrophy, age greater than 60 years, smoking, hyperten‐
sion, and dyslipidemia. The specific number of risk factors that should be used to prompt 
testing remains to be determined, but the committee considers 3 or more as reasonable (Class 
IIb; Level of Evidence C).”
Step 3: Non‐invasive testing
Most common non‐invasive stress testing modalities include dobutamine stress echocar‐
diogram (DSE) and MPI. The diagnostic accuracy of these tests varies with sensitivity rang‐
ing from 0.29 to 0.92 (MPI) 0.44–0.89 (DSE) and specificity of around 0.67–0.89 (MPI) and 
0.71–0.94 (DSE) [78]. MPI accuracy can be effected by presence of balanced ischemia result‐
ing in more false negative results. Recently, coronary computed tomography angiography 
(CCTA) was shown to be a reliable test with high sensitivity (93%) and a high negative pre‐
dictive value (97%) for diagnosing obstructive CAD before kidney transplantation. Hybrid 
imaging techniques like combining CCTA and SPECT have a sensitivity and specificity of 
67 and 86% [82]
Step 4: Coronary angiography
Based on the noninvasive testing, coronary angiography is performed as needed to determine 
the presence and extent of obstructive CAD.
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Step 5: Revascularization
Revascularization is done either with PCI with stent or CABG after assessment of extent of 
obstructive CAD and risk factors like diabetes as per the ACC/AHA guidelines for management 
of stable ischemic heart disease.
7. Cardiovascular risk in renal transplant patients
Renal transplant (RT) has dramatically improved the survival and quality of life for success‐
ful recipients. Despite advancements in surgical methods and medical management of RT 
patients, cardiovascular disease (CVD) remains the leading cause of death in patients with 
functional grafts.
The risk of CVD improves after RT when compared to patients with end‐stage renal disease 
(ESRD) awaiting transplantation. However, mortality due to CVD is ten times higher in renal 
transplant recipients than the age and sex‐matched general population [83, 84].
The increased risk of CVD cannot be explained by traditional risk factors alone.Non‐tradi‐
tional risk factors in RT patient population also play a pivotal role [85].
Traditional CVD risk factors include Hypertension, Diabetes Mellitus, Dyslipidemia, Tobacco 
use, and Obesity. In this section the effect of immunosuppressive agents on these traditional 
risk factors will be discussed.
7.1. Non‐traditional risk factors
In addition to traditional CVD risk factors, RT patients develop specific risk factors related to 
ESRD including but not limited to endothelial dysfunction, electrolyte imbalances (calcium 
and phosphorous), anemia and variations in the plasma volume following dialysis.
A retrospective study using database from Données Informatisées et Validées en 
Transplantation (DIVAT) evaluated 244 RT patients post‐transplant for 1 year for ST‐segment 
elevation myocardial infarction (STEMI), non‐ST‐segment elevation myocardial infarction 
(NSTEMI), new onset atrial fibrillation or ventricular fibrillation, and death from cardiovas‐
cular diseases.
The results revealed that a past medical history of cardiovascular disease (Hazard Ratio 
(HR) = 2.06, p = 0.03), left ventricular hypertrophy (HR = 2.04, p = 0.04) and abnormal myo‐
cardial perfusion imaging (HR = 2.18, p = 0.05) were associated with a higher risk of early 
cardiovascular event [86].
7.2. Left ventricle hypertrophy
LVH is a common co‐morbidity observed in chronic kidney disease (CKD) and end‐stage 
renal disease (ESRD) patients [87]. Multiple factors have been implicated as the cause of LVH 
Cardiovascular Aspects of Patients with Chronic Kidney Disease and End-Stage Renal Disease
http://dx.doi.org/10.5772/intechopen.69294
115
including over‐activation of the sympathetic nervous system, volume overload, hypertension, 
inhibition of nitric oxide, arterial stiffness, diabetes, dyslipidemia, endothelial dysfunction, 
and anemia of chronic disease. Electrocardiographic (ECG) evidence of LVH in the first year 
after RT was found to be an independent risk factor for death and subsequent congestive 
heart failure [88]. Persistent or de novo LVH is also a strong independent risk factor for death 
after 5 years, confirming the continuing importance of LVH even in the late post‐transplant 
period [88].
The presence of LVH is a important prognostic factor for CVD mortality and morbidity in RT 
patients. Whether a successful renal transplantation can reverse LVH still remains a debatable 
issue [87].
7.3. Over‐activation of the sympathetic nervous system
To entertain the hypothesis that development of LVH may be connected to excessive activa‐
tion of the sympathetic nervous system, the effect of pre‐transplant bilateral native nephrec‐
tomy on left ventricular mass and function has been evaluated. A study group of 32 patients 
who had undergone pre‐transplant bilateral native nephrectomy were compared to 32  control 
group patients and evaluated with echocardiography and/or cardiac magnetic resonance 
(CMR) [89].
After a 90‐month follow‐up, bilateral native nephrectomy before transplantation was associ‐
ated with a lower left ventricular mass index (LVMI; p = 0.001), left atrial volume index (LAVI; 
p = 0.004), and a lower grade (grade I) of left ventricular diastolic dysfunction [89]. In compar‐
ison with controls, the study group had lower systolic blood pressure (p = 0.04) and required 
a fewer number of anti‐hypertensive medications (p = 0.001) [89].
7.4. Inflammatory state
Pro‐inflammatory markers have also been studied in RT patient population. Neopterin is syn‐
thesized by macrophages upon stimulation by interferon‐gamma. Serum neopterin is a marker 
of a pro‐inflammatory state in RT patients. Clinical trial data has revealed that Neopterin is 
associated with cardiovascular events and all‐cause mortality in renal transplant patients.
The Assessment of LEscol in Renal Transplant (ALERT) trial prospectively analyzed RT 
patients with stable graft for an association between serum neopterin and subsequent clinical 
events: graft loss, major cardiovascular events (MACE) and all‐cause mortality.The long‐term 
follow‐up suggests that neopterin‐to‐creatinine ratio is significantly associated with MACE 
(p = 0.009) and all‐cause mortality (p = 0.002) [90].
7.5. Proteinuria
A prospective trial of 90 RT patients with normal graft function in the post‐transplantation 
period (3–5 years) investigated the association between proteinuria and graft/patient survival 
and to determine whether proteinuria may be a predictor for cardiovascular disease. High‐
grade (≥500 mg/24 hours) proteinuria in RT patients is strongly associated with poor graft 
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survival and increased risk of cardiovascular events [91]. These findings were similar to CKD 
patients without transplant as previously described.
7.6. Anemia
According to the follow‐up data from the ALERT study, anemia is a predictor of graft loss 
but not associated with an increased incidence of cardiovascular morbidity and mortality or 
all‐cause mortality in RT patients [92].
7.7. Immunosuppressive therapy
RT patients are usually on a combination of following maintenance medications:
Corticosteroids: Prednisone.
Antiproliferative agents: Mycophenolate Mofetil and Azathioprine.
Calcineurin inhibitors: Tacrolimus and Cyclosporine.
mTOR inhibitors: Sirolimus and Everolimus.
No immunosuppressive drug has been directly associated with cardiovascular events. 
However, immunosuppressive drugs impact the traditional risk factors and play a crucial role.
8. Hypertension
8.1. Corticosteroids
According to the historical literature, corticosteroids were believed to cause elevated blood 
pressure by water and salt retention via an effect on the mineralocorticoid receptor. However, 
recent data points that blockade of NO formation by inhibition of both inducible and endo‐
thelial nitric oxide synthase (eNOS), inhibition of transmembrane arginine transport and 
 inhibition of the synthesis of the NOS cofactor BH4 play a prominent role [93].
8.2. Antiproliferative agents
Anti‐proliferative agents were thought to worsen hypertension in RT patients. However 
recent studies in patients with systemic lupus erythematosus suggests an improved blood 
pressure control with the use of mycophenolate mofetil.
8.3. Calcineurin inhibitors
Cyclosporine monotherapy induces hypertension to the same extent as corticosteroids [94]. 
The mechanism by which cyclosporine and tacrolimus increase blood pressure is complex. 
One proposed mechanism is that cyclosporine stimulates transmembrane influxes of 
calcium, thereby leading to vascular smooth muscle cell contraction and vasoconstriction. 
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Other  proposed mechanisms include increased production of endothelin 1 (ET‐1), transform‐
ing growth factor (TGF), renin, and inhibition of NO production by multiple pathways.
Recent data suggests that tacrolimus results in less renal vasoconstriction than cyclosporine. 
RT patients being treated with tacrolimus and equivalent dosages of corticosteroids require 
fewer anti‐hypertensive medications than patients being treated with cyclosporine [95].
9. Dyslipidemia
9.1. Corticosteroids
Corticosteroids increase total cholesterol, low‐density lipoprotein (LDL), high‐ density lipo‐
protein (HDL), and hepatic synthesis of very low‐density lipoprotein (VLDL) [96]. Corti‐
costeroids lead to decreased LDL receptor synthesis and subsequent expression, thereby 
leading to reduced uptake and degradation of LDL [97].
9.2. Calcineurin inhibitors
Cyclosporine increases total cholesterol, LDL, and VLDL but decreases HDL. Cyclosporine 
decreases the activity of lipoprotein lipase (LPL) leading to hypertriglyceridemia. It also 
impairs the clearance of LDL by a similar mechanism to corticosteroids [98].
When comparing patients on tacrolimus versus cyclosporine, tacrolimus‐treated patients 
have lower total cholesterol, LDL, and triglycerides. The levels of HDL are comparable. In 
a randomized, prospective trial evaluating RT patients with conversion from cyclosporine 
to tacrolimus, total cholesterol improved significantly by a mean of 0.5 mmol/L, LDL by 
0.35 mmol/L and triglycerides by 0.4 mmol/L. These results were sustained up to 2 years after 
conversion [99].
9.3. mTOR inhibitors
Sirolimus is notorious for causing hyperlipidemia; increasing VLDL and LDL. One hypothesis is 
that sirolimus increases hepatic production of triglycerides and secretion of VLDL [100]. In clini‐
cal trials evaluating serum lipid profile, the addition of sirolimus 10 milligrams to cyclosporine 
and corticosteroids for 6 weeks increased both total cholesterol and LDL by 50% and triglycer‐
ides by almost 100%. The effects were fully reversible after discontinuation of sirolimus [100].
10. Diabetes mellitus
Post‐transplantation diabetes mellitus (PTDM) has evolved into a concerning challenge in 
RT patients. Approximately one‐third of nondiabetic kidney transplant recipients develop 
persistent impaired glucose metabolism by 6 months post‐transplantation [101]. Risk factors 
for PTDM include age, obesity, African American race and Hispanic ethnicity, family history 
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and impaired glucose tolerance. Additionally, transplant related risk factors also play a role: 
immunosuppressive medications, HLA mismatch, donor gender, type of underlying renal 
disease and viral infections (HCV and CMV) [102].
The implications of PTDM in patient outcomes are not well established, but data from the 
USRDS/UNOS have shown that PTDM increases the risk of post‐transplant myocardial 
infarction [103].
10.1. Corticosteroids
Corticosteroids lead to development of PTDM by enhancing insulin resistance. PTDM is 
reversible by cessation of corticosteroids.
10.2. Antiproliferative agents
There is no data suggesting that mycophenolate mofetil or azathioprine play a role in devel‐
opment of PTDM.
10.3. Calcineurin inhibitors
RT patients receiving calcineurin inhibitors have a higher incidence of PTDM. The etiology is 
impairment in pancreatic beta‐cell secretory function [104]. Dose reduction has been shown to 
reverse diabetes in majority of the affected patients. The incidence of PTDM with tacrolimus 
is postulated to be as high as 20%. The higher incidence of PTDM with tacrolimus versus 
cyclosporine is believed to be due to stronger potency of tacrolimus in calcineurin inhibition 
than cyclosporine [105].
Tacrolimus leads to PTDM in a dose‐dependent manner. It leads to complete reversible inhi‐
bition of the insulin gene transcription with no acute effects on insulin secretion or the glucose 
uptake by insulin. Therefore, in majority of patients, PTDM is reversible after reducing the 
dose of tacrolimus and withdrawing corticosteroids.
10.4. mTOR inhibitors
There is no data suggesting that sirolimus or everolimus plays a role in development of PTDM.
11. Management of immunosuppressive agents in controlling  
risk factors
11.1. Corticosteroids
Corticosteroids negatively impact blood pressure, lipid profile, and glucose metabolism. 
Randomized trials have shown that corticosteroid withdrawal or corticosteroid‐free immu‐
nosuppression improves hypertension, dyslipidemia, and glucose metabolism [106].
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11.2. Calcineurin inhibitors
In patients receiving cyclosporine combined with mycophenolate mofetil, a 50% reduction 
in cyclosporine dose or complete cyclosporine withdrawal from a mycophenolate mofetil or 
sirolimus‐based regimen results in fewer anti‐hypertensive medications [106]. Tacrolimus 
increases the risk of PTDM more than cyclosporine, therefore, switching from tacrolimus to 
cyclosporine may lead to improvement in PTDM.
12. Conclusion
Renal transplantation is the single most effective intervention for reducing CV risk in appro‐
priately selected patients with ESRD. Even though renal transplant has significantly improved 
survival for successful recipients, CVD remains the leading cause of death in patients with 
functional grafts [107].
In addition to traditional CVD risk factors, RT patients develop specific risk factors related to 
ESRD including but not limited to left ventricular hypertrophy, over‐activation of the sympa‐
thetic nervous system, pro‐inflammatory state, and proteinuria.
Post‐transplantation, patients are maintained on a regimen of immunosuppressive medica‐
tions. Even though immunosuppressive drugs have not been directly associated with car‐
diovascular events, they play pivotal role in risk associated with traditional risk factors of 
hypertension, dyslipidemia, and diabetes.
Strategies targeting transplant‐specific CV risk factors should include optimization of renal 
function, limiting risk of rejection, avoidance of PTDM and anticipation of CV side effects of 
immunosuppression.
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